| SPERO THERAPEUTICS |
| USA |
| Gesundheit |
| US84833T1034 / A2H63F |
| 2HA (Frankfurt) / SPRO (NASDAQ) |
| FRA:2HA, ETR:2HA, 2HA:GR, NASDAQ:SPRO |
| - |
| https://sperotherapeutics.. |
|
Spero Therapeutics Inc. is a biopharmaceutical company focused on developing novel treatments for infectious diseases, particularly those caused by antibiotic-resistant bacteria. The primary function of Spero Therapeutics is to address the growing gl..
>Volltext.. |
| 122.87 Mio. EUR |
| 91.07 Mio. EUR |
| 51.65 Mio. EUR |
| -0.02 Mio. EUR |
| 7.43 Mio. EUR |
| 0.13 EUR |
| 2.51 Mio. EUR |
| 34.88 Mio. EUR |
| -10.94 Mio. EUR |
| 4.54 |
| 91.81% |
| - |
| - |
| - |
| - |
| - |
| SPERO THERAPEUTICS, SPERO THERAPEUTIC |
| 04.04.26 |
|